Home > Insider Trading > Filing (0001140361-17-019827)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1588972	Recro Pharma Inc.	REPH	()	CA

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1440771	Stonepine Capital Management, Llc	919 Nw Bond Street Suite 204 Bend OR 97703		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-05-09	195,059	$7.64	2,461,950	No	4	S	Indirect	See Notes
Common Stock	Disposition	2017-05-09	33,070	$7.64	2,428,880	No	4	S	Indirect	See Notes
Common Stock	Disposition	2017-05-10	6,412	$7.77	2,422,468	No	4	S	Indirect	See Notes
Common Stock	Disposition	2017-05-10	1,088	$7.77	2,421,380	No	4	S	Indirect	See Notes
Common Stock	Disposition	2017-05-11	7,696	$7.96	2,413,684	No	4	S	Indirect	See Notes
Common Stock	Disposition	2017-05-11	1,304	$7.96	2,412,380	No	4	S	Indirect	See Notes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Notes
No	4	S	Indirect	See Notes
No	4	S	Indirect	See Notes
No	4	S	Indirect	See Notes
No	4	S	Indirect	See Notes
No	4	S	Indirect	See Notes

Footnotes

The filers (the "Filers") are Stonepine Capital Management, LLC (the "General Partner"), Stonepine Capital, L.P. (the "Partnership"), Jon M. Plexico and Timothy P. Lynch. The General Partner is the general partner and investment adviser of investment funds, including the Partnership (collectively, the "Funds"). Mr. Plexico and Mr. Lynch are the General Partner's managers and control persons. These securities are held directly by the Funds for the benefit of their investors and are indirectly beneficially owned by the General Partner and Mr. Plexico and Mr. Lynch as the General Partner's control persons. The General Partner is filing this Form 4 for itself and the other Filers.
The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Each Filer disclaims beneficial ownership of these securities except to the extent of that Filer's pecuniary interest therein.
These securities were sold by the Partnership, which held 2,076,784 shares after the transaction on May 9, 2,070,372 shares after the transaction on May 10 and 2,062,676 shares after the transaction on May 11.
These securities were sold by the other Funds.